TABLE 1.
Demographics, disease medical history, and cognitive features of participants.
| NC | SCD | F/Z/χ2 | P-value | |||
|
|
|
|||||
| Normal BMI (n = 29) |
High BMI (n = 17) |
Normal BMI (n = 38) |
High BMI (n = 27) |
|||
| Age (years)a | 66.24 ± 4.57 | 68.53 ± 4.05 | 65.39 ± 4.72 | 65.85 ± 4.61 | 6.459 | 0.091 |
| Gender [n (%)]b | 7.184 | 0.066 | ||||
| Male | 6 (20.7) | 6 (35.3) | 10 (26.3) | 28 (73.7) | ||
| Female | 23 (79.3) | 11 (64.7) | 28 (73.7) | 13 (48.1) | ||
| BMI (kg/m2)a | 21.60 ± 1.64 | 26.23 ± 1.76 | 21.81 ± 1.37 | 25.90 ± 2.64 | 79.395 | <0.001 |
| Education (years)a | 11.12 ± 2.45 | 11.56 ± 2.32 | 12.54 ± 2.81 | 12.28 ± 2.58 | 1.916 | 0.131 |
| Hypertension [n (%)]b | 7 (24.1) | 9 (52.9) | 14 (36.8) | 14 (51.9) | 5.977 | 0.113 |
| Hyperlipidemia [n (%)]b | 5 (17.2) | 5 (29.4) | 5 (13.2) | 5 (18.5) | 2.118 | 0.548 |
| T2DM [n (%)]b | 5 (17.2) | 3 (17.6) | 9 (23.7) | 6 (22.2) | 0.552 | 0.907 |
| Medicine [n (%)]b | 13 (44.8) | 9 (52.9) | 20 (52.6) | 17 (63.0) | 1.855 | 0.603 |
| MoCA scorea | 26.97 ± 1.05 | 27.59 ± 1.12 | 27.53 ± 1.03 | 27.22 ± 1.12 | 7.045 | 0.070 |
| HAMD scorea | 2.55 ± 2.10 | 1.94 ± 2.14 | 3.47 ± 2.55 | 2.26 ± 2.18 | 6.548 | 0.088 |
| HAMA scorea | 3.28 ± 2.58 | 2.76 ± 1.95 | 3.00 ± 1.79 | 3.04 ± 1.48 | 1.042 | 0.791 |
aContinuous variable, one-way ANOVA is adopted, and mean ± SD is used for statistical description.
bCategorical variables were statistically described by chi-square test, and n (%) is used for statistical description.
BMI, body mass index; T2DM, type II diabetes mellitus; MoCA, the Montreal Cognitive Assessment; HAMD, the Hamilton Depression Scale; HAMA, the Hamilton Anxiety Scale. Medicine: medication history refers to the last 3-month routine medication self-reported by subjects when receiving the questionnaire of this study, and mainly records the use of drugs that control hypertension, hyperlipidemia, and T2DM. In addition, any other medications the participant has used within the last 3 months were also recorded.